Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
Early Detection Is Key to Higher Cure Rates in Ovarian Cancer "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
One in Five BRCA-Positive Breast Cancer Patients Able to Conceive Disease-free survival comparable between patients who did and did not become pregnant Dec 12, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments Dec 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer Domenica Lorusso details the importance of modern radiotherapy in this regimen Dec 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
Emicizumab Safe, Effective, in Infants With Hemophilia A More than half of children in study had no treated bleeds at follow-up of more than 100 weeks Dec 10, 2023
Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says Dec 10, 2023
Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant Dec 10, 2023
Grappling With Our Deadliest Cancer Here are essential steps to improve lung cancer screening Dec 10, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
Completely Oral Regimen Effective, Feasible in APL 97% of patients alive and relapse-free at 3 years Dec 10, 2023
Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors No difference for survival outcomes for annual versus around every 2 years Dec 09, 2023
AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cell Also in TTHealthWatch: mail-in cervical cancer screening kits Dec 09, 2023 podcast
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer However, the surgery did reduce risk of contralateral breast cancer Dec 09, 2023
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA? Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease Dec 08, 2023
EUS-Guided Gastroenterostomy Better Option for Cancer-Related Duodenal Blockages However, technique and technology are not widespread Dec 08, 2023
Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer Datopotamab deruxtecan was safe and boosted quality of life Dec 08, 2023
Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC But better safety profile versus continued pembrolizumab plus chemotherapy Dec 08, 2023
Milestone Gene Therapies for Sickle Cell Disease Greenlit by FDA Casgevy and Lyfgenia approved for one-time treatment of sickle cell disease Dec 08, 2023
Study 'Underscores' Value of Early Fertility Counseling for Breast Cancer Patients Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy Dec 08, 2023
More Awareness Needed of Heart Events Tied to Breast Cancer Drugs, Experts Say Myriad clinical manifestations of cardiotoxicity must be diagnosed, treated promptly Dec 08, 2023
Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer Promising early results with pembrolizumab, nivolumab but event-free survival data still pending Dec 07, 2023
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients Association strongest in patients with overweight, obesity Dec 07, 2023
Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drug News, features, and commentary about cancer-related issues Dec 07, 2023
The Treatment Landscape for Cervical Cancer Has Changed Our experts discuss the impact of new options and approaches available in the field Dec 07, 2023 video
No Benefit to Adjuvant-Only Immunotherapy in Early TNBC Neoadjuvant administration of immunotherapy remains the preferred approach Dec 07, 2023
De-Escalating Breast Cancer Treatment Feasible After Response to Neoadjuvant Chemo Study showed no increase in disease progression when omitting regional nodal irradiation Dec 07, 2023
Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer Adding agent to T-DM1 resulted in 2-month progression-free survival improvement Dec 06, 2023
FDA Approves Oral Factor B Inhibitor for Paroxysmal Nocturnal Hemoglobinuria Iptacopan tops C5 Inhibitors for sustained hemoglobin levels, eliminating need for transfusion Dec 06, 2023
TULSA Effective in Controlling Prostate Cancer Long-Term At 5 years, median PSA was reduced by 90% Dec 05, 2023
